CNTX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
8.0M
-46.8%
15.0M
+60.2%
9.3M
-32.3%
13.8M
+30.1%
10.6M
R&D
5.7M
-54.4%
12.5M
+78.6%
7.0M
-40.8%
11.8M
+35.8%
8.7M
SG&A
2.2M
-7.9%
2.4M
+4.7%
2.3M
+18.6%
2.0M
+4.0%
1.9M
Operating Income
-7961408
+46.8%
-14967491
-60.2%
-9343799
+32.3%
-13804646
-30.1%
-10610480
EBITDA
-7953939
+46.8%
-14960844
-60.2%
-9339112
+32.3%
-13800581
-30.1%
-10606414
Net Income
-7623706
+47.6%
-14558426
-67.7%
-8680572
+33.4%
-13025607
-34.4%
-9693237
EPS (Basic)
$-0.08
+46.7%
$-0.15
-66.7%
$-0.09
+35.7%
$-0.14
-40.0%
$-0.10
EPS (Diluted)
$-0.08
+46.7%
$-0.15
-66.7%
$-0.09
+35.7%
$-0.14
-40.0%
$-0.10
Shares (Diluted)
95.2M
+0.0%
95.2M
+0.0%
95.2M
+0.0%
95.2M
-0.0%
95.2M
Context Therapeutics (CNTX) — Financials